Discarded Blood Tests May Offer Life-Saving Information
|
By LabMedica International staff writers Posted on 08 Sep 2014 |

Image: Scanning electron micrograph of Staphylococcus epidermidis, the commonest coagulase-negative staphylococci found on the skin (Photo courtesy of the US National Institute of Allergy and Infectious Diseases).
Blood culture isolates are the cornerstone of adequate antibiotic treatment, but many blood cultures are contaminated with bacteria residing on the skin, and the most common contaminants are coagulase-negative staphylococci (CoNS).
Such contaminated cultures are mostly disregarded and discarded but in fact these contaminated cultures contain diagnostic information such as the antibiotic resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated subsequently from the same patient.
Clinical scientists at the Sackler Faculty of Medicine (Tel Aviv, Israel) conducted a retrospective study on patients with positive blood cultures from 2009 to 2012. Data included patient demographics, hospitalization records, comorbidities, blood culture results and date of death. The cohort consisted of 2,518 patients with 5,290 blood cultures, where 1,124 patients had 1,664 blood cultures with CoNS contaminants.
High overall CoNS resistance predicted high overall resistance of the subsequent bacterial isolates for Gram-positive and Gram-negative bacteria. The resistance of CoNS contaminants to a specific antibiotic predicted the resistance of the subsequent bacterial isolates to that antibiotic and highly resistant CoNS isolates were associated with higher short-term mortality.
The team noted that most hospital patients are treated at the outset with broad spectrum antibiotics. Days later, after initial test results are known, clinicians replace broad spectrum antibiotics with more precise narrow-spectrum antibiotics, which treat the specific bacteria identified by the blood sample. Narrow spectrum antibiotics are better for the body because they target specific bacteria as opposed to an entire microenvironment. Moreover, broad spectrum antibiotics might result in altered bacterial environments of the skin and gastro-intestinal tract, promoting inflammation and the emergence of resistant pathogens.
Gideon Y Stein, MD, PhD, a lead author of the study said, “Because we have found a direct correlation between resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated from the same patient, the results of these “junk” samples can be used to predict patient mortality and correct empirical antibiotic therapy. This should serve as an additional, noninvasive, diagnostic tool.” The study was published in the September issue of the Journal of Antimicrobial Chemotherapy.
Related Links:
Tel Aviv University Sackler Faculty of Medicine
Such contaminated cultures are mostly disregarded and discarded but in fact these contaminated cultures contain diagnostic information such as the antibiotic resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated subsequently from the same patient.
Clinical scientists at the Sackler Faculty of Medicine (Tel Aviv, Israel) conducted a retrospective study on patients with positive blood cultures from 2009 to 2012. Data included patient demographics, hospitalization records, comorbidities, blood culture results and date of death. The cohort consisted of 2,518 patients with 5,290 blood cultures, where 1,124 patients had 1,664 blood cultures with CoNS contaminants.
High overall CoNS resistance predicted high overall resistance of the subsequent bacterial isolates for Gram-positive and Gram-negative bacteria. The resistance of CoNS contaminants to a specific antibiotic predicted the resistance of the subsequent bacterial isolates to that antibiotic and highly resistant CoNS isolates were associated with higher short-term mortality.
The team noted that most hospital patients are treated at the outset with broad spectrum antibiotics. Days later, after initial test results are known, clinicians replace broad spectrum antibiotics with more precise narrow-spectrum antibiotics, which treat the specific bacteria identified by the blood sample. Narrow spectrum antibiotics are better for the body because they target specific bacteria as opposed to an entire microenvironment. Moreover, broad spectrum antibiotics might result in altered bacterial environments of the skin and gastro-intestinal tract, promoting inflammation and the emergence of resistant pathogens.
Gideon Y Stein, MD, PhD, a lead author of the study said, “Because we have found a direct correlation between resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated from the same patient, the results of these “junk” samples can be used to predict patient mortality and correct empirical antibiotic therapy. This should serve as an additional, noninvasive, diagnostic tool.” The study was published in the September issue of the Journal of Antimicrobial Chemotherapy.
Related Links:
Tel Aviv University Sackler Faculty of Medicine
Latest Microbiology News
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Channels
Clinical Chemistry
view channel
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more
Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. Earlier detection,... Read moreMolecular Diagnostics
view channel
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more
Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more
Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
Cancer screening is intended to reduce mortality, but policy decisions often depend on early indicators that may not fully reflect true survival benefit. The emergence of blood-based tests capable of detecting... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read morePathology
view channel
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen, a company focused on specialized diagnostics, has announced a strategic collaboration with Oxford Nanopore Technologies, which develops nanopore-based sequencing technology, to validate Werfen’s... Read more








